Literature DB >> 11753546

Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation.

E M Tegg1, A E Griffiths, R M Lowenthal, D M Tuck, R Harrup, K A Marsden, D M Jupe, S Ragg, J P Matthews.   

Abstract

We studied interleukin-6 (IL-6) levels on the day of transplantation in 31 patients undergoing autologous haemopoietic stem cell transplantation (SCT) (either peripheral blood stem cell transplantation (PBSCT) or bone marrow transplantation (BMT)) for neoplastic diseases to determine if there was a relationship between IL-6 level and rate of haemopoietic recovery, length of stay in hospital, and survival. There was no apparent delay in post-transplant recovery associated with elevated IL-6 levels. However, increased values of IL-6 tended to be associated with an increased length of stay in hospital (P = 0.083). There was a highly significant adverse association between higher IL-6 levels and survival following transplantation (P = 0.0001). This association remained significant (P = 0.013) in the uniform subgroup of patients with malignant lymphoma with chemosensitive disease who had undergone BMT (that is, excluding patients who had undergone PBSCT) (n = 13). Knowledge of IL-6 levels on the day of transplant has the potential to provide valuable prognostic information in patients undergoing autologous haemopoietic SCT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753546     DOI: 10.1038/sj.bmt.1703272

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Authors:  J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  Effect of sertraline on complications and survival after hematopoietic stem-cell transplantation, a double-blind, placebo-controlled clinical study.

Authors:  Maria Tavakoli-Ardakani; Raziyeh Kheshti; Mehrpooya Maryam
Journal:  Int J Hematol       Date:  2017-08-16       Impact factor: 2.490

3.  Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Amittha Wickrema; Shira Dinner; Lucy A Godley; Masha Kocherginsky; Olatoyosi Odenike; Elizabeth S Rich; Wendy Stock; Jodie Ulaszek; Richard A Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

4.  Association between Interlukin-6 (IL-6), Interlukin-10 (IL-10) and depression in patients undergoing Hematopoietic stem cell transplantation.

Authors:  Maria Tavakoli-Ardakani; Maryam Mehrpooya; Mahshid Mehdizadeh; Abbas Hajifathali; Alireza Abdolahi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-04-01

Review 5.  Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

Authors:  Tor Henrik Anderson Tvedt; Elisabeth Ersvaer; Anders Aune Tveita; Øystein Bruserud
Journal:  Front Immunol       Date:  2017-06-08       Impact factor: 7.561

6.  Post-transplant Complication With TAFRO Features in a Patient With Acute Myeloid Leukemia.

Authors:  Kyosuke Yamaguchi; Yasushi Kubota; Hiroo Katsuya; Toshihiko Ando; Shinya Kimura
Journal:  Cureus       Date:  2022-03-31

Review 7.  Role of Biomarkers as Predictors of Infection and Death in Neutropenic Febrile Patients after Hematopoietic Stem Cell Transplantation.

Authors:  Karin Massaro; Silvia Figueiredo Costa
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-10-15       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.